Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 2Acute Kidney Injury 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Rare Diseases 1Paraproteinemias 1Neuromyelitis Optica 1Neurologic Manifestations 1Nervous System Diseases 1Neoplasms, Plasma Cell 1Myelitis, Transverse 1Myasthenia Gravis 1Multiple Sclerosis 1Mental Disorders 1Kidney Diseases 1Hematologic Diseases 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1Autoimmune Diseases 1

Interventions

XENP 1595 2Standard of Care 2Selective Serotonin Reuptake Inhibitors 1Plasma Exchange 1Methylphenidate 1Memory and Learning Tests 1Interviews as Topic 1Immunoglobulins 1Forest Therapy 1Dialectical Behavior Therapy 1Cognitive Behavioral Therapy 1Clomipramine 1Citalopram 1Cari-D-Tect 1Behavior Therapy 1Animal Assisted Therapy 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mental Disorders × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡